No individual CpG provided superior predictive performance compared to the mean of all CpGs.<h4>Conclusion</h4>A clinically relevant, survival informed three-tier classification of MGMT promoter methylation is proposed for the pyrosequencing kit analyzing CpGs 76-79 in glioblastoma. The gene discussed is MGMT; the disease is glioblastoma.